Scientific references - Arocell TK 210 ELISA

Breast Cancer

Tribukait B, Jagarlamudi KK, Bergh K, Hatschek T
Quantitation of cell loss in breast cancer during neoadjuvant treatment (NACT) assessed by serum thymidine kinase protein concentration (sTK1)
Annals of Oncology, Vol 28: Issue Suppl 10, 1 November 2017.
https://academic.oup.com/annonc/article/28/suppl_10/mdx655.023/4652389

Kiran Kumar J, Aronsson AA, Pilko G, Zupan M, Kumer K, Fabjan T, Osredkar J, Eriksson S.
A Clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease.
Tumor Biol. Published online 14 April 2016
https://link.springer.com/article/10.1007/s13277-016-5024-z

Jagarlamudi KK, Hansson LO, Eriksson S.
Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.
BMC Cancer 2015 Feb 18;15:66.
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1073-8

He E, X XH, Guan H, Chen Y, Chen ZH, Pan ZL, Tang LL Hu GZ, Li Y, Zhang M, Zhou J, Eriksson S, Fornander T, Skog S.
Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin’s lymphoma.
Nucleosides Nucleotides Nucleic Acids. 2010, 29 (4-6): p.352-8.
https://www.tandfonline.com/doi/abs/10.1080/15257771003738535?journalCode=lncn20

Carlsson L, Larsson A, Lindman H.
Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer.
Ups J Med Sci. 2009;114(2):116-20.
https://www.ncbi.nlm.nih.gov/pubmed/19396699

He, Q, Mao Y, Wu J, Decker C, Merza M, Wang N, Eriksson S, Castro J Skog S.
Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas.
Int J. Oncology 2004 Oct 25 (4): p. 945-953.
https://www.spandidos-publications.com/ijo/25/4/945

Bagegni N, Thomas S, Liu N, et al.
Serum thymidine kinase 1 as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early stage breast cancer receiving neoadjuvant palbociclib.
Breast Cancer Res 2017; 19: 123
https://www.ncbi.nlm.nih.gov/pubmed/29162134

Jagarlamudi KK, Wang L, Eriksson S
Doxorubicin effects on leukemia and breast cancer cells in culture on the TK1 protein levels using AroCell TK 210 ELISA: a tool for drug development.
Nucleosides Nucleotides Nucleic Acids, Published online 06 December 2018.
https://www.tandfonline.com/doi/abs/10.1080/15257770.2018.1478094?journalCode=lncn20

Prostate Cancer

Jagarlamudi, KK Zupan, M Kumer, K, et al.
The combination of AroCell TK 210 ELISA with Prostate Health Index or prostate‐specific antigen density can improve the ability to differentiate prostate cancer from noncancerous conditions.
The Prostate. 2019; 1‐ 8.
https://doi.org/10.1002/pros.23791

Jagarlamudi KK, Tribukait B, Zupan M, K. Kumer K, Fabjan T, Osredkar J, Smrkoli T, Eriksson S.
The TK 210 ELISA can measure increased TK1 protein levels in sera from prostate cancer patients with different Gleason scores.
Tumor Biol. 2015 36 (Suppl 1) S34-S35, 2015.
https://link.springer.com/article/10.1007/s13277-015-4009-7

Hematological Malignancies

Votava T, Topolcan O, Holubec L Jr, Cerna Z, Sasek L, Finek J, Kormunda S.
Changes of serum thymidine kinase in children with acute leukemia.
Anticancer Res. 2007 Jul-Aug;27(4A):1925-8
https://www.ncbi.nlm.nih.gov/pubmed/17649797

Gatt ME, Goldschmidt N, Kalichman I, Friedman M, Arronson AC, Barak V.
Thymidine kinase levels correlate with prognosis in aggressive lymphoma and can discriminate patients with a clinical suspicion of indolent to aggressive transformation.
Anticancer Res. 2015 May;35(5):3019-26.
https://www.ncbi.nlm.nih.gov/pubmed/25964590

Suzuki K, Terui Y, Yokoyama M, Ueda K, Nishimura N, Mishima Y, Sakajiri S, Tsuyama N, Takeuchi K, Hatake K.
Prognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone. Leuk Lymphoma. 2013 Nov;54(11):2412-7.
https://www.ncbi.nlm.nih.gov/pubmed/23488601

Procházka V, Faber E, Raida L, Langová K, Indrák K, Papajík T.
High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma.
Leuk Lymphoma. 2012 Jul;53(7):1306-10.
https://www.ncbi.nlm.nih.gov/pubmed/22263569

Konoplev SN, Fritsche HA, O’Brien S, Wierda WG, Keating MJ, Gornet TG, St Romain S, Wang X, Inamdar K, Johnson MR, Medeiros LJ and Bueso-Ramos CE
High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia.
Am J Clin Pathol 134: 472-477, 2010.
https://www.ncbi.nlm.nih.gov/pubmed/20716805

Kok M, Bonfrer JM, Korse CM, de Jong D, Kersten MJ.
Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin’s lymphoma.
Tumour Biol. 2003 Jan-Feb;24(1):53-60.
https://www.ncbi.nlm.nih.gov/pubmed/12743427

Poley S, Stieber P, Nüssler V, Pahl H, Fateh-Moghadam A.
Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma.
Anticancer Res. 1997 Jul-Aug;17(4B):3025-9.
https://www.ncbi.nlm.nih.gov/pubmed/9329592

Micke O, Schäfer U, Wörmann B, Hiddemann W, Willich N.
Circadian variations of interleukin-2 receptors, serum thymidine kinase and beta-2-microglobulin in patients with non-Hodgkin’s lymphoma and normal controls.
Anticancer Res. 1997 Jul-Aug;17(4B):3007-10
https://www.ncbi.nlm.nih.gov/pubmed/9329587

Other Cancer

Li Z, Wang Y, Ma J, He S, Zhou J, He E, Skog S.
Transient increase in serum thymidine kinase 1 within one week after surgery of patients with carcinoma.
Anticancer Res. 2010, 30(4): p. 1295-9.
https://www.ncbi.nlm.nih.gov/pubmed/20530443

Li Z, Wang Y, He J, Ma J, Zhao L, Chen H, Li N Zhou J, He H, Skog S.
Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas.
Eur J Cancer Prev. 2010, 19(4): p. 313-8.
https://www.ncbi.nlm.nih.gov/pubmed/20479645

Chen Y, Ying M, Chen Y, Hu M, Lin Y, Chen D, Li X, Zhang M, Yun X, Zhou J, He E, Skog S.
Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings.
Int J Clin Oncol. 2010 Aug;15(4):359-68. Epub 2010 Apr 1.
https://www.ncbi.nlm.nih.gov/pubmed/20354751

Brockenbrough JS, Morihara JK, Howes SE, Stern JE, Rasey JS, Wiens LW, Feng Q, Vesselle H.
Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation.
J Histochem Cytochem. 2009 Nov;57(11):1087-97. Epub 2009 Aug 3.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762886/

Luo P, He E, Eriksson S, Zhou J, Hu G, Zhang J, Skog S.
Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker.
Eur J Cancer Prev. 2009 Jun;18(3):220-4.
https://www.ncbi.nlm.nih.gov/pubmed/19282758

van Waarde A, Elsinga PH.
Proliferation markers for the differential diagnosis of tumor and inflammation.
Curr Pharm Des. 2008;14(31):3326-339.
https://www.ncbi.nlm.nih.gov/pubmed/19075707

Topolcan O, Holubec L Jr.
The role of thymidine kinase in cancer diseases.
Expert Opin. Med Diagn. 2008 Feb;2(2):129-41.
https://www.ncbi.nlm.nih.gov/pubmed/23485133

Zhang, J, Jia Q, Zou S, Zhang P, Zhang X, Skog S, Luo P, Zhong W, He Q.
Thymidine kinase 1: A proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients.
Oncology Reports, 2006, 15 (2): p. 455-461.
https://www.ncbi.nlm.nih.gov/pubmed/16391869

Zou, L, Zheng PG, Zou S, Li Y, He Q.
The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer.
Int J Biol Markers, 2002.Apr-Jun 17(2): p. 135-140.
https://www.ncbi.nlm.nih.gov/pubmed/12113581

O´Neill KL, Buckwalter MR, Murray BK.
Thymidine kinase: diagnostic and prognostic potential.
Expert Rev. Mol. Diagn. 2001, Nov 1(4):p.428-433
http://www.ncbi.nlm.nih.gov/pubmed/11901857

Z.F. Jiang, M. Wang, J.L. Xu,
Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
Life Sci. 2018 Feb 1;194:1-6
https://www.ncbi.nlm.nih.gov/pubmed/29247745

Thymidine Kinase 1

Per Venge, Ann-Katrin Eriksson, Sofia Holmgren, Lena Douhan-Håkansson, Christer Peterson, Shengyuan Xu, Staffan Eriksson, Daniel Garwicz, Anders Larsson, Karlis Pauksen
HNL (Human Neutrophil Lipocalin) and a multimarker approach to the distinction between bacterial and viral infections
Journal of Immunological Methods,2019, Published online 23 June 2019, ISSN 0022-1759.
https://doi.org/10.1016/j.jim.2019.06.018

Jagarlamudi KK, Shaw M
Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker
Biomarkers in Medicine, Vol.12: Issue 9, p:1035–1048, Published online 24 July 2018.
https://www.ncbi.nlm.nih.gov/pubmed/30039979

Jagarlamudi KK, Holmgren S, Venge P, Eriksson S.
Evaluation of an improved version of the AroCell TK 210 ELISA for determining thymidine kinase 1 protein level in serum samples.
Tumor Biol. (2016) 37(Suppl 1): 1.
https://link.springer.com/article/10.1007/s13277-016-5287-4

Eriksson S, Kiran Kumar J, Nilsson O, Venge P, Aronsson AC.
The TK 210 ELISA is a robust method to determine thymidine kinase 1 protein levels in serum samples.
Tumor Biol. 2015 36 (Suppl 1) S57, 2015.
https://link.springer.com/article/10.1007/s13277-015-4009-7

Zhou J, He E, Skog S.
The proliferation marker thymidine kinase 1 in clinical use.
Mol Clin Oncol 2013 Jan;1(1):18-28. Epub 2012 Sep 4.
https://www.ncbi.nlm.nih.gov/pubmed/24649117

Hanan S, Jagarlamudi KK, Liya W, Ellen H, Staffan E.
Quaternary structures of recombinant, cellular, and serum forms of thymidine kinase 1 from dogs and humans.
BMC Biochem 2012 Jun 28;13:12.
https://www.ncbi.nlm.nih.gov/pubmed/22741536

Chen YL, Eriksson S, Chang ZF.
The regulation and functional contribution of thymidine kinase 1 in repair of DNA damage.
J Biol Chem. 2010 Aug 27;285(35):27327-35. Epub 2010 Jun 16.
https://www.ncbi.nlm.nih.gov/pubmed/20554529

Wellin M, Kosinska U, Mikkelsen NE, Carnrot C, Zhu C, Wong L, Eriksson S, Munch-Petersen B, Eklund H.
Structures of thymidine kinase 1 of human and mycoplasma origin.
Proc. Natl. Acad. Sci. USA 2004, Dec 28; 101 (52): p.17970-17975.
https://www.ncbi.nlm.nih.gov/pubmed/15611477

Öhrvik A, Lindh M, Einarsson R, Grass J, Eriksson S.
Sensitive nonradiometric method for determining Thymidine kinase 1 activity.
Clin Chem 2004 50 (9): p.1597-1606.
https://www.ncbi.nlm.nih.gov/pubmed/15247154

Wu, C, Yang R, Zhou J, Bao S, Zou L, Zhang P, Mao Y, Wu J, He Q.
Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1.
J Immunol Methods, 2003.Jun 1 277 (1-2): p. 157-169
https://www.ncbi.nlm.nih.gov/pubmed/12799048

Eriksson, S, Munch-Petersen B, Johansson K, Eklund H.
Structure and function of cellular deoxyribonucleoside kinases.
Cell Mol Life Sci, 2002. Aug; 59 (8): p. 1327-1346.
http://www.ncbi.nlm.nih.gov/pubmed/12363036

Johansson, K, Ramaswamy S, Ljungcrantz C, Knecht W, Piskur J, Munch-Petersen B, Eriksson S, Eklund H.
Structural basis for substrate specificities of cellular deoxyribonucleoside kinases.
Nat Struct Biol, 2001. Jul 8 (7): p. 616-620.
https://www.ncbi.nlm.nih.gov/pubmed/11427893

Wang, N, He Q, Skog S, Eriksson S, Tribulait B.
Investigation on cell proliferation with a new antibody against thymidine kinase 1.
Anal Cell Pathol, 2001. 23 (1): p. 11-19.
https://www.ncbi.nlm.nih.gov/pubmed/11790855

He, Q, Skog S, Wong N, Eriksson S, Tribukait B.
Characterization of a peptide antibody against C-terminal part of a human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation.
Eur J Cell Biol, 1996. 70 (2): p. 117-124.
https://www.ncbi.nlm.nih.gov/pubmed/8793383

Breast Cancer

Prostate Cancer

Hematological Malignancies

Other Cancer

Thymidine Kinase 1

Subscription for news and press releases